Coronavirus disease (COVID-19) vaccine can alter the body’s immunological balance leading to autoimmune disease in rare cases. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is one of the autoimmune diseases which have been rarely reported to appear post-COVID-19 vaccine. Herein, we report the case of a 47-year-old woman who developed acute renal failure few days after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine. Corticosteroids along with azathioprine were used for the management.

© 2022 S. Karger AG, Basel

The humongous medical, financial, and social impact of coronavirus disease (COVID-19) necessitated the rapid implementation of vaccination. Several types of vaccines were found using novel pathways such as mRNA delivered via lipid nanoparticles, viral vectors, inactivated virus, and protein subunits [1]. These vaccines were significantly effective in reducing COVID-19-related mortality [1].

The induction of an autoimmune/autoinflammatory response, such as vaccine-induced immune thrombotic thrombocytopenia and immune-mediated myocarditis, are some of the rare side effects reported with different types of vaccines [2, 3]. Interestingly, different types of vasculitides, including anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, were reported in the context of the Pfizer-BioNTech COVID-19 vaccine [4]. As a consequence, multiple ongoing clinical trials are currently studying the safety profile of COVID-19 vaccines [5].

In this case report, we illustrate the case of a healthy woman who developed acute renal failure few days following the Pfizer-BioNTech COVID-19 vaccine. This patient was successfully treated with oral corticosteroids and azathioprine.

A previously healthy 47-year-old woman presented to the primary care clinic for bilateral flank pain, generalized weakness, and bilateral lower extremity swelling that started 3 days following the first dose of Pfizer-BioNTech COVID-19 vaccine. No shortness of breath or hemoptysis was reported. Vital signs were within normal limits, including a blood pressure of 129/76 mm Hg. Physical examination was significant for bilateral lower extremity edema reaching the knees. No sacral edema was noted. Costovertebral angle tenderness was negative. Otherwise, the examination was unremarkable, including a regular rate rhythm, with normal S1 and S2, no murmurs, and palpable peripheral pulses.

Urinalysis was positive for proteins, red blood cells of 40–50/high power field, and white blood cells of 8–10/high power field. Urine protein/creatinine ratio was significantly elevated at 1,777 mg/g. Laboratory investigations were compatible with acute kidney injury as the serum creatinine was 2.91 mg/dL (baseline 0.8 mg/dL measured 7 months prior to presentation), urea was 208 mg/dL, and eGFR was 18 mL/min/1.73 m2. In addition, bicarbonate was decreased at 17 mEq/L. The complete blood count was significant for leukocytosis (white blood count 14.99 × 103/µL) with neutrophil predominance of 82.8%. Inflammatory markers were elevated with C-reactive protein of 2.34 mg/dL (normal range: 0.8–1.0 mg/dL). The extractable nuclear antigen profile was positive for anti-neutrophil cytoplasmic antibody (ANCA) IgG myeloperoxidase (MPO) at 2.8 units/mL (normal <1 units/mL). The IgG class ANCA directed to proteinase 3 (PR3) titers were within normal limits (normal <1 units/mL). Complement levels and other serologic tests were unremarkable. A CT scan of the chest was negative for any lung involvement. A kidney biopsy revealed changes of fibrous crescents with interstitial fibrosis and tubular atrophy with negative immunofluorescence compatible with a systemic disease mediated by ANCA (Fig. 1a, b). The patient was started on intravenous methylprednisolone for 3 days and prednisone 50 mg daily thereafter along with azathioprine 50 mg twice daily.

a Two glomeruli are globally obsolescent (sclerosed) with capillary tuft of glomeruli with cellular crescents showing few or no inflammatory cell elements. b On periodic acid-Schiff stain, the glomerular basement membranes of unaffected segments show wrinkling and thickening of the glomerular basement membrane. Tubules reveal focal atrophy and interstitium is minimally infiltrated by chronic inflammatory cells.

Serum creatinine trended down to 2.01 mg/dL 2 weeks after treatment initiation. Urine protein/creatinine ratio also trended down to 862 mg/g. In a follow-up visit to the clinic 3 months after initial presentation, the patient reported a better functional status. The lower extremity edema completely resolved. Serum creatinine was 1.23 mg/dL in the 3- month follow-up visit.

Despite being rare events, vaccines have been long thought to induce autoimmune diseases, such as swine flu vaccine inducing Guillain-Barré syndrome [6]. ANCA-associated vasculitis (AAV) has been also reported in the context of vaccination. For example, multiple reports have illustrated a temporal relationship between AAV and influenza vaccination [7].

Besides the appearance of autoinflammatory/autoimmune phenomena in COVID-19 patients [8], different types of COVID-19 vaccines have been very rarely linked with several autoimmune diseases, such as rheumatoid arthritis [9] and lupus nephritis [10]. Vasculitis induction has been also reported in the context of COVID-19 vaccine. Both induction of vasculitis and a flare of a pre-existing vasculitis have been described post-COVID-19 vaccine [11-13]. One type of vasculitides, the AAV, has been also rarely illustrated to be induced secondary to different types of COVID-19 vaccines, including the Pfizer-BioNTech vaccine (Table 1). Furthermore, a case series of 29 patients who developed glomerular disease post-severe acute respiratory syndrome coronavirus 2 immunization was reported in the literature [14]. Only two of these cases had a complete recovery. Out of all 29 cases, six had a crescentic glomerulonephritis. Four out of 10 ANCA-positive glomerulonephritis cases had the disease occurring after the Pfizer-BioNTech COVID-19 vaccine, none of which had a complete recovery, although the treatment is unclear. There was no overall increase in the incidence of biopsy-proven glomerular disease when compared to the era prior to the COVID-19 pandemic [14]. The glomerular disease secondary to COVID-19 vaccination was deemed to be rare, although it should be monitored as a potential adverse event [14].

Positive ANCA and AAV cases following Pfizer-BioNTech COVID-19 vaccine

Our case is unique in the rapid onset of symptoms and the onset post the first dose in particular [15-17]. It is important to note that the presence of fibrous crescents and interstitial fibrosis in the kidney biopsy might point to a chronic process. The AAV might have been silent in our patient and exacerbated after COVID-19 vaccination. A recent consensus statement on COVID-19 vaccination in patients with immune-mediated kidney disease highlighted the rarity of induction/flare of immune-mediated kidney disease post-COVID-19 vaccination [21]. The consensus statement indicated that these rare cases respond to immunosuppression and mainly occur post-second vaccination dose.

Acute kidney injury has been rarely associated with severe acute respiratory syndrome coronavirus 2 infection [17] and COVID-19 vaccine [22, 23]. Although there is no recommendation to randomly check serum creatinine in COVID-19 patients or those recently vaccinated, an elevated serum creatinine or abnormal urinalysis in this population warrants further investigation keeping in mind a possible autoimmune process.

In conclusion, COVID-19 vaccines have substantial benefits. Rarely, autoimmune processes have been described post-vaccination. AAV is an example of an autoimmune disease that can be induced or flared up from a silent state by COVID-19 vaccines. A high index of suspicion regarding the presence of an autoimmune renal process is needed whenever a recently COVID-19-vaccinated individual presents for acute kidney injury.

An ethics statement is not applicable because this study is based exclusively on published literature. The patient has given her written informed consent to publish this case (including publication of images).

The authors have no conflicts of interest to declare.

The authors have received no funds to publish this report.

Georges El Hasbani took care of reviewing the literature and writing this case. Imad Uthman generated the idea and provided the images.

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.